Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

CYLD anticorps (C-Term)

CYLD Reactivité: Humain ELISA, IHC, IF Hôte: Lapin Polyclonal unconjugated
N° du produit ABIN7174362
  • Antigène Voir toutes CYLD Anticorps
    CYLD (Cylindromatosis (Turban Tumor Syndrome) (CYLD))
    Épitope
    • 15
    • 6
    • 4
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 269-435, C-Term
    Reactivité
    • 40
    • 24
    • 18
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Humain
    Hôte
    • 34
    • 6
    • 1
    Lapin
    Clonalité
    • 35
    • 6
    Polyclonal
    Conjugué
    • 23
    • 3
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    Cet anticorp CYLD est non-conjugé
    Application
    • 33
    • 14
    • 7
    • 5
    • 4
    • 4
    • 3
    • 3
    • 1
    • 1
    • 1
    • 1
    ELISA, Immunohistochemistry (IHC), Immunofluorescence (IF)
     Réactivité croisée
    Humain
    Purification
    >95%, Protein G purified
    Immunogène
    Recombinant Human Ubiquitin carboxyl-terminal hydrolase CYLD protein (269-435AA)
    Isotype
    IgG
    Top Product
    Discover our top product CYLD Anticorps primaire
  • Indications d'application
    Recommended dilution: IHC:1:20-1:200, IF:1:50-1:200,
    Restrictions
    For Research Use only
  • Format
    Liquid
    Buffer
    Preservative: 0.03 % Proclin 300
    Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4
    Agent conservateur
    ProClin
    Précaution d'utilisation
    This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    -20 °C,-80 °C
    Stockage commentaire
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • Antigène
    CYLD (Cylindromatosis (Turban Tumor Syndrome) (CYLD))
    Autre désignation
    CYLD (CYLD Produits)
    Synonymes
    anticorps BRSS, anticorps CDMT, anticorps CYLD1, anticorps CYLDI, anticorps EAC, anticorps MFT, anticorps MFT1, anticorps SBS, anticorps TEM, anticorps USPL2, anticorps 2010013M14Rik, anticorps 2900009M21Rik, anticorps C130039D01Rik, anticorps mKIAA0849, anticorps cyld, anticorps LRRGT00003, anticorps Rp1, anticorps Rp1h, anticorps CYLD lysine 63 deubiquitinase, anticorps cylindromatosis (turban tumor syndrome), a, anticorps CYLD, anticorps Cyld, anticorps cylda
    Sujet

    Background: Deubiquitinase that specifically cleaves \'Lys-63\'-linked polyubiquitin chains. Has endodeubiquitinase activity. Plays an important role in the regulation of pathways leading to NF-kappa-B activation (PubMed:12917689, PubMed:12917691). Contributes to the regulation of cell survival, proliferation and differentiation via its effects on NF-kappa-B activation (PubMed:12917690). Negative regulator of Wnt signaling (PubMed:20227366). Inhibits HDAC6 and thereby promotes acetylation of alpha-tubulin and stabilization of microtubules (PubMed:19893491). Plays a role in the regulation of microtubule dynamics, and thereby contributes to the regulation of cell proliferation, cell polarization, cell migration, and angiogenesis (PubMed:18222923, PubMed:20194890). Required for normal cell cycle progress and normal cytokinesis (PubMed:17495026, PubMed:19893491). Inhibits nuclear translocation of NF-kappa-B. Plays a role in the regulation of inflammation and the innate immune response, via its effects on NF-kappa-B activation (PubMed:18636086). Dispensable for the maturation of intrathymic natural killer cells, but required for the continued survival of immature natural killer cells. Negatively regulates TNFRSF11A signaling and osteoclastogenesis (By similarity). Involved in the regulation of ciliogenesis, allowing ciliary basal bodies to migrate and dock to the plasma membrane, this process does not depend on NF-kappa-B activation (By similarity). Also able to remove linear (\'Met-1\'-linked) polyubiquitin chains to regulate innate immunity: recruited to the LUBAC complex and, together with OTULIN, restricts linear polyubiquitin formation on RIPK2 in response to NOD2 stimulation (PubMed:26670046, PubMed:26997266).

    Aliases: BRSS antibody, CDMT antibody, Cyld antibody, CYLD gene antibody, CYLD_HUMAN antibody, CYLD1 antibody, CYLDI antibody, cylindromatosis (turban tumor syndrome) antibody, cylindromatosis 1 antibody, Deubiquitinating enzyme CYLD antibody, EAC antibody, HSPC057 antibody, KIAA0849 antibody, MFT antibody, MFT1 antibody, Probable ubiquitin carboxyl terminal hydrolase CYLD antibody, SBS antibody, TEM antibody, turban tumor syndrome antibody, Ubiquitin carboxyl-terminal hydrolase CYLD antibody, ubiquitin specific peptidase like 2 antibody, ubiquitin thioesterase CYLD antibody, Ubiquitin thiolesterase CYLD antibody, Ubiquitin-specific processing protease CYLD antibody, Ubiquitin-specific-processing protease CYLD antibody, USPL2 antibody

    UniProt
    Q9NQC7
    Pathways
    Apoptose, Activation of Innate immune Response
Vous êtes ici: